Senseonics Holdings (Senseonics Holdings) ROCE % : -48.01% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Senseonics Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Senseonics Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -48.01%.

Senseonics Holdings ROCE % Historical Data

The historical data trend for Senseonics Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senseonics Holdings ROCE % Chart

Senseonics Holdings Annual Data

Trend

Jun14

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-151.26

-1,253.31

-286.02

98.44

-36.89

Senseonics Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															48.54	16.46	-51.43	-63.23	-48.01

Senseonics Holdings ROCE % Calculation

Senseonics Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-49.282	/	( ( (177.673 - 31.471)	+	(138.22 - 17.257) )	/ 2 )
	=	-49.282	/	( (146.202	+	120.963)	/ 2 )
	=	-49.282	/	133.5825
	=	-36.89 %

Senseonics Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-61.872	/	( ( (154.065 - 17.302)	+	(138.22 - 17.257) )	/ 2 )
	=	-61.872	/	( ( 136.763	+	120.963 )	/ 2 )
	=	-61.872	/	128.863
	=	-48.01 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Senseonics Holdings (AMEX:SENS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Senseonics Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Senseonics Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Senseonics Holdings (Senseonics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Senseonics Holdings Inc (AMEX:SENS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

6L6:Germany 6L6:Germany

Address

20451 Seneca Meadows Parkway, Germantown, MD, USA, 20876-7005

Website

https://www.senseonics.com

Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of the glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.

Executives

Sharon Larkin	director	C/O SENSEONICS HOLDINGS, INC., 20451 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Douglas A Roeder	director	160 BOVET RD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Frederick T. Sullivan	officer: Chief Financial Officer	C/O SENSEONICS HOLDINGS, INC., 20451 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Mukul Jain	officer: VP Operations, Qual & Reg	20451 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Edward Fiorentino	director	1350 KENNICOTT DRIVE, LAKE FOREST IL 60045
Mirasol Panlilio	officer: VP Global Sales & Marketing	20451 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Timothy T Goodnow	director, officer: President & Chief Exec Officer	20451 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Francine Kaufman	officer: Chief Medical Officer	C/O SENSEONICS HOLDINGS, INC., 20451 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Kenneth L Horton	officer: GC & Corp. Development Advisor	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Nick B. Tressler	officer: Chief Financial Officer	C/O SENSEONICS HOLDINGS, INC., 20451 SENECA MEADOWS PARKWAY, GERMANTOWN MD 208786
Anthony R. Raab	director	C/O SENSEONICS HOLDINGS, INC., 20451 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
John Marotta	director	C/O SENSEONICS HOLDINGS, INC., 20451 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Stephen P Defalco	director	ONE EXETER STREET, BOSTON MA 02116
Douglas S Prince	director	20 TILESTON STREET, PH4, BOSTON MA 02113
Edelman Steven	director	C/O SENSEONICS HOLDINGS, INC., 20451 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876